U.S. markets close in 5 hours 54 minutes
  • S&P 500

    -15.66 (-0.43%)
  • Dow 30

    -184.98 (-0.62%)
  • Nasdaq

    -10.16 (-0.08%)
  • Russell 2000

    -15.81 (-0.85%)
  • Crude Oil

    +0.38 (+0.85%)
  • Gold

    +7.40 (+0.41%)
  • Silver

    +0.12 (+0.49%)

    +0.0008 (+0.07%)
  • 10-Yr Bond

    -0.0170 (-1.93%)

    -0.0013 (-0.10%)

    -0.1040 (-0.10%)

    -33.79 (-0.18%)
  • CMC Crypto 200

    +10.69 (+2.88%)
  • FTSE 100

    -40.79 (-0.63%)
  • Nikkei 225

    +131.27 (+0.50%)

Are Insiders Selling Coherus BioSciences, Inc. (NASDAQ:CHRS) Stock?

Simply Wall St

It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So we'll take a look at whether insiders have been buying or selling shares in Coherus BioSciences, Inc. (NASDAQ:CHRS).

Do Insider Transactions Matter?

It is perfectly legal for company insiders, including board members, to buy and sell stock in a company. However, such insiders must disclose their trading activities, and not trade on inside information.

We don't think shareholders should simply follow insider transactions. But logic dictates you should pay some attention to whether insiders are buying or selling shares. For example, a Columbia University study found that 'insiders are more likely to engage in open market purchases of their own company’s stock when the firm is about to reveal new agreements with customers and suppliers'.

Check out our latest analysis for Coherus BioSciences

The Last 12 Months Of Insider Transactions At Coherus BioSciences

Over the last year, we can see that the biggest insider sale was by the Chairman, Dennis Lanfear, for US$631k worth of shares, at about US$19.49 per share. That means that an insider was selling shares at around the current price of US$19.27. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

In the last twelve months insiders netted US$676k for 35398 shares sold. Insiders in Coherus BioSciences didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NasdaqGM:CHRS Recent Insider Trading, October 21st 2019
NasdaqGM:CHRS Recent Insider Trading, October 21st 2019

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership of Coherus BioSciences

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Coherus BioSciences insiders own 2.7% of the company, worth about US$36m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Coherus BioSciences Insiders?

The fact that there have been no Coherus BioSciences insider transactions recently certainly doesn't bother us. Still, the insider transactions at Coherus BioSciences in the last 12 months are not very heartening. The modest level of insider ownership is, at least, some comfort. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.